INTRODUCTION {#s1}
============

Gliomas are the most common primary brain tumors, accounting for 31% of all central nervous system tumors and 81% of malignant CNS tumors \[[@R1]\], and are classified into grades from I to IV on the basis of histopathological and clinical criteria established by the World Health Organization (WHO) \[[@R2]\]. Grade I gliomas are often circumscribed and generally curable with surgical resection alone \[[@R1], [@R2]\]. In contrast, Grade II and III gliomas are invasive and progress to higher grade lesions, with a poor prognosis \[[@R1], [@R2]\]. Glioblastomas, which are WHO grade IV gliomas, are traditionally classified as either primary or secondary if they developed from lower-grade gliomas \[[@R2]\]. Analyzing the specific genetic characteristics of gliomas has improved the understanding of glioma genesis and predictions of prognosis, and allows for the use of targeted treatments on an individual basis \[[@R3], [@R4]\]. IDH (Isocitrate Dehydrogenase) mutations are among the most common gene alterations in gliomas. Mutations in IDH genes occur in up to 80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, and in less than 10% of primary glioblastomas \[[@R5], [@R6]\], indicating that this mutation plays a key role in early gliomatogenesis \[[@R7]\]. Patients with grade II, III, or IV gliomas carrying IDH mutations have better overall survival \[[@R4], [@R8]\]. Additionally, accounting for IDH mutation status eliminates age differences in the prevalence of different WHO~2007~ grade gliomas \[[@R9], [@R10]\]. These results indicate that additional characteristics in addition to WHO~2007~ grade should be considered when classifying gliomas.

Studies of IDH-1 mutations are frequently based on DNA sequencing, a method which is usually considered robust. However, the IDH1 R132H antibody (clone H09) is more convenient, reliable, and consistent for the detection of IDH1^R132H^ protein, and is widely used in clinical diagnosis and research \[[@R11]--[@R15]\]. In this study, in addition to IDH-1^R132H\ mut^ protein levels, Ki-67 index and mutant P53 and MGMT (O (6)-methylguanineDNA methyltransferase) protein levels were explored in a cohort of glioma patients from a single institution in China. The predictive value of IDH-1^R132H\ mut^ levels for glioma patient prognosis was also investigated in this study.

RESULTS {#s2}
=======

IDH-1 R132H mutations in various histological types {#s2_1}
---------------------------------------------------

We analyzed the distribution of IDH1^R132H\ mut^ in 33 astrocytomas (A), 41 oligodendrogliomas (O), and 82 oligoastrocytomas (OA). The IDH1^R132H^ mutation was present less often in A, at 60.6%, than in O or OA (87.8% and 84.1% respectively, *p*=0.006) (Table [1](#T1){ref-type="table"}). We also investigated the presence of IDH1^R132H\ mut^ in 126 anaplastic gliomas, including 32 anaplastic astrocytomas, 39 anaplastic oligodendrogliomas, and 55 anaplastic oligoastrocytomas. The distribution of IDH-1 mutation did not differ among the anaplastic glioma subtypes (Table [1](#T1){ref-type="table"}). There were 300 primary glioblastomas (pGBM), 62 secondary glioblastomas (sGBM), and 26 glioblastomas with an oligodendroglioma component (GBMO). The rate of IDH-1^R132H\ mut^ was 6.3% in pGBM, lower than that in sGBM (71.0%, *p*\<0.001) and GBMO (46.2%, *p*\<0.001). IDH-1^R132H\ mut^ was also more frequent in sGBM than in GBMO (*p*\<0.05) (Table [1](#T1){ref-type="table"}).

###### Distribution of IDH-1 R132H mutation in different grades of glioma

  WHO~2007~ grade   total   Gender (F/M)   Age (median), range   Age (mean) ± SEM   *p* value   IDH-1^R132H\ mut^   *p* value
  ----------------- ------- -------------- --------------------- ------------------ ----------- ------------------- -----------
  **II**            156     68/88          38, 20-70             38.54 ± 0.77                   125 (80.1%)         
  A                 33      13/20          39, 20-61             39.76 ± 1.95                   20 (60.6%)          
  O                 41      20/21          38, 20-70             38.07 ± 1.30       0.715       36 (87.8%)          **0.006**
  OA                82      35/47          37.5, 20-56           38.29 ± 1.07                   69 (84.1%)          
  **III**           126     59/67          44, 18-72             43.13 ± 1.09                   72 (57.1%)          
  AA                32      15/17          42, 18-72             42.75 ± 2.30                   17 (53.1%)          
  AO                39      19/20          47, 18-65             44.62 ± 1.95       0.655       25 (64.1%)          0.567
  AOA               55      25/30          42, 19-69             42.31 ± 1.60                   30 (54.5%)          
  **IV**            388     142/246        51, 18-82             51.47 ± 0.76                   75 (19.3%)          
  pGBM              300     109/191        53, 18-82             51.47 ± 0.76                   19 (6.3%)           
  sGBM              62      23/39          44.5, 18-71           43.69 ± 1.40       **0.000**   44 (71.0%)          **0.000**
  GMBO              26      10/16          47.5, 23-66           48.23 ± 2.29                   12 (46.2%)          

IDH1 R132H mutations and age {#s2_2}
----------------------------

The 272 patients carrying IDH-1 ^R132H\ mut^ were younger than the 398 patients without the mutation (39.79 ± 0.61 vs. 50.33 ± 0.66 years, *p*\<0.001) (Table [2](#T2){ref-type="table"}). The association between IDH-1^R132H^ mutation and younger age in astrocytic tumors contributed to this difference (Table [2](#T2){ref-type="table"}). Furthermore, we analyzed age differences in patients with astrocytic neoplasms. Patients with pGBM (51.47 ± 0.76, n=300) were older than those with AA (42.75 ± 2.30, n=32; *p*=0.001) or A (39.76 ± 1.95, n=33; *p*\<0.001). Patients with AA also tended to be older than those with A, but this difference did not reach statistical significance. There were no differences in age among patients with A, AA, or pGBM in either the IDH-1^R132H-wt^ (*p=*0.347) or IDH-1^R132H-mut^ (*p*=0.062) groups.

###### Relationship between age and IDH-1 R132H mutation in gliomas

  WHO~2007~ Grade   IDH-1^R132H\ mut^      IDH-1^R132H\ wt^   *p* value                             
  ----------------- ---------------------- ------------------ ---------------------- -------------- -----------
  **Total**         39.79 ± 0.61 (n=272)   40, 20-70          50.33 ± 0.66 (n=398)   52, 18-82      **0.000**
  **II**            37.58 ± 0.82 (n=125)   37, 20-70          42.45 ± 1.89 (n=31)    44, 20-61      **0.011**
  A                 34.05 ± 1.98 (n=20)    34, 20-55          48.54 ± 2.35 (n=13)    49, 32-61      **0.000**
  O                 38.22 ± 1.30 (n=36)    38, 26-70          37.00 ± 5.70 (n=5)     43, 20-49      0.844
  OA                38.26 ± 1.18 (n=69)    37, 20-56          38.46 ± 2.48 (n=13)    40, 26-54      0.946
  **III**           41.08 ± 1.22 (n=72)    41, 20-65          45.87 ± 1.90 (n=54)    46.50, 18-72   **0.029**
  AA                37.88 ± 2.16 (n=17)    38, 20-51          48.27 ± 3.87 (n=15)    50, 18-72      **0.022**
  AO                45.52 ± 2.16 (n=25)    46, 26-65          43.00 ± 3.92 (n=14)    48.5, 18-65    0.543
  AOA               39.20 ± 1.80 (n=30)    39.5, 20-59        46.04 ± 2.63 (n=25)    45, 19-69      **0.032**
  **IV**            42.24 ± 1.19 (n=75)    42, 22-63          51.88 ± 0.73 (n=313)   53, 18-82      **0.000**
  pGBM              41.58 ± 2.57 (n=19)    40, 22-63          52.14 ± 0.78 (n=281)   54, 18-82      **0.001**
  sGBM              41.77 ± 1.45 (n=44)    42, 23-61          48.39 ± 3.06 (n=18)    49, 18-71      **0.030**
  GBMO              45.00 ± 3.43 (n=12)    44.5, 23-63        51.00 ± 2.99 (n=14)    51, 32-66      0.197

IDH-1 R132H mutation and other molecular markers {#s2_3}
------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, 68.0% (185/272) and 32.0% (87/272) of the IDH-1 ^R132H-mut^ and IDH-1 ^R132H-wt^ groups, respectively, had Ki-67\<30. A, O, and OA patients with lower WHO grades also tended to have Ki-67\<30, independent of IDH status. Mutant p53 was more prevalent in the IDH-1 ^R132H\ mut^ group (55.9%, 152/272) than in the IDH-1 ^R132H\ wt^ group (23.9%, 95/398). However, mutant p53 was only present in grade II-III astrocytomas. Decreased MGMT protein levels were observed more often in IDH-1 ^R132H-mut^ patients than in IDH-1 ^R132H-wt^ patients (76.1% vs. 58.8%, *p*\<0.001). However, there was no consistent relationship between MGMT proteins level and IDH-1^R132H^ status within any of the individual glioma subtypes (Table [3](#T3){ref-type="table"}).

###### Co-occurrence of IDH-1 R132H mutation and other molecular markers

  Glioma              Ki-67   *p* value   p53 mut   *p* value   MGMT   *p* value                          
  ------------------- ------- ----------- --------- ----------- ------ ----------- ----------- ----- ---- -----------
  IDH-1^R132H\ mut^           185         87        **0.000**   120    152         **0.000**   207   65   **0.000**
  IDH-1^R132H\ wt^    149     249         303       95          234    164                                
  IDH-1^R132H\ mut^   A       20          0         **0.000**   4      16          **0.017**   16    4    0.924
  AA                  12      5           3         14          13     4                                  
  pGBM                6       13          11        8           14     5                                  
  IDH-1^R132H\ wt^    A       13          0         **0.000**   9      4           **0.003**   8     5    0.718
  AA                  8       7           7         8           7      8                                  
  pGBM                81      200         232       49          156    125                                
  IDH-1^R132H\ mut^   O       36          0         **0.000**   32     4           0.090       30    6    0.616
  AO                  16      9           18        7           21     4                                  
  OA                  69      0           27        42          58     11                                 
  IDH-1^R132H\ mut^   AOA     15          15        **0.000**   9      21          0.603       21    9    0.067
  GBMO                4       8           3         9           7      5                                  
  IDH-1^R132H\ wt^    OA      13          0         **0.001**   7      6           0.103       9     4    1.000
  AOA                 13      12          9         16          17     8                                  
  GBMO                10      4           10        4           10     4                                  

IDH-1 R132H mutation and prognosis {#s2_4}
----------------------------------

Follow-up data was available for 165 pGBM, 50 sGBM, 22 GBMO, 14 AA, 28 AO, 47 AOA, 13OA, 30 O, and 2 A patients. In multivariate analysis, we found that increased IDH-1^R132H\ mut^, low MGMT levels, and Ki-67\<30 were associated with better prognosis.

### IDH-1^R132H^ mutation and Ki-67\<30 {#s2_4_1}

IDH-1^R132H^ mutation was associated with better prognosis \[median 58.700 months (95% CI 23.946--93.454) vs. 15.370 months in wild-type patients (95% CI 13.190--17.550); *p*\<0.001, Breslow test\]. The median OS of 36.230 months (95% CI 31.103--41.357) in patients with Ki-67\<30 was higher than the OS of 15.370 months (95% CI 12.842--17.898) in patients with Ki-67≥30 (*p*\<0.001, Kaplan-Meier method and Breslow test). We subdivided IDH-1^R132H\ mut^ or IDH-1^R132H\ wt^ gliomas based on Ki-67\<30, and found differences in mOS among the four groups (Figure [1a](#F1){ref-type="fig"}). Patients with Ki-67\<30 had better prognoses, regardless of whether they had IDH-1 ^R132H-mut^ \[(median not reached) vs. 19.000 months (95% CI 13.754--24.246); *p*\<0.001, Breslow test, Figure [1b](#F1){ref-type="fig"}\] or IDH-1^R132H\ wt^ \[median 17.400 months (95% CI 13.627--21.173) vs. 13.270 months (95% CI 11.141--15.399); *p*=0.039, Breslow test, Figure [1c](#F1){ref-type="fig"}\]. However, OS did not differ between IDH-1^R132H\ mut^/Ki-67≥30 and IDH-1^R132H\ wt^ /Ki-67\<30 patients (*p=*0.751, Breslow test).

![Kaplan--Meier survival curves and Breslow tests for IDH-1^R132H\ mut^ and Ki-67≥30 in diffuse gliomas\
Patient were separated into groups based on IDH-1R132H mut and Ki-67 index; clinical outcomes differed among the groups **a.** Ki-67\<30 was associated with longer overall survival in both IDH-1R132H mut **b.** and IDH-1R132H wt **c.** patients.](oncotarget-07-31393-g001){#F1}

### IDH-1^R132H^ mutation and MGMT {#s2_4_2}

The mOS of 15.670 months (95% CI 13.273--18.067) in MGMT-positive patients was shorter than the mOS of 32.500 months (95% CI 22.439--42.561) observed in MGMT-negative patients (*p*\<0.001, Breslow test). Furthermore, mOS differed among IDH-1^R132H-mut^-MGMT^neg^ (58.700 months, 95% CI 31.437--85.963), IDH-1^R132H\ mut^-MGMT^pos^ (19.570 months, 95% CI 11.018-28.122), IDH-1^R132H\ wt^-MGMT^neg^ (16.300 months, 95% CI 13.188--19.412) and IDH-1^R132H-WT^-MGMT^pos^ (13.830 months, 95% CI 11.019-16.641) patients (*p*\<0.001, Breslow test, Figure [2a](#F2){ref-type="fig"}). MGMT^neg^ patients in the IDH-1^R132H\ mut^ group (*p*=0.006, Breslow test, Figure [2b](#F2){ref-type="fig"}), but not in the IDH-1^R132H\ wt^ group (*p*=0.102, Breslow test, Figure [2c](#F2){ref-type="fig"}), had a much better prognosis than MGMT^pos^ patients. No difference was observed in OS between IDH-1^R132H-mut^-MGMT^pos^ and IDH-1^R132H-WT^-MGMT^neg^ patients (*p*=0.471, Breslow test).

![Kaplan--Meier survival curves and Breslow tests for IDH-1R132H mut and MGMT proteins in diffuse gliomas\
Overall survival differed depending on IDH-1R132H mut status and MGMT protein levels **a.** Lower MGMT levels were associated with better clinical outcomes in IDH-1 R132H mut **b.** but not in IDH-1R132H wt **c.** patients.](oncotarget-07-31393-g002){#F2}

DISCUSSION {#s3}
==========

The most frequent IDH-1 mutation type in glioma is R132H, which accounts for 88.2%-92.7% of mutations in this gene \[[@R16]--[@R18]\]. In an IHC study specifically detecting IDH-1^R132H\ mut^ using the H09 antibody, the rates were 83.0% in A II, 90.0% in O II, 100% OA II, 81.0% in A III, 88.0% in O III, 87.5% in OA III, 4% in glioblastoma, and 71.4% in sGBM \[[@R14]\]. The frequency of IDH-1 mutations ranged from 4-7.6% in primary glioblastoma and 73-88% in secondary glioblastoma \[[@R19], [@R20]\]. The IDH-1 R132H mutation rates detected here are similar to the ranges published previously \[[@R14], [@R17], [@R19], [@R21]\].

Also in agreement with previous findings, patients harboring IDH-1^R132H\ mut^ in all grades of glioma in our study were younger than those without the mutation \[[@R6], [@R17], [@R22], [@R23]\]. Moreover, IDH-1^R132H\ mut^ was present much more frequently in younger A, AA, AOA, pGBM, and sGBM patients. Other studies suggest a strong association between age and the prevalence of all WHO~2007~ glioma subtypes \[[@R6], [@R17]\]. In this regard, the differences between our findings and previous studies were likely due, at least in part, to small numbers of patients with particular gliomas subtypes examined here. A II IDH^mut^ and A III IDH^mut^ patients did not differ in age in a previous study \[[@R9]\]. While patients with A III were older than those with A II in our study, both groups were significantly younger than those with pGBM. However, there were no differences in patient age after they were separated based on IDH-1^R132H\ mut^. Thus, the differences in age associated with different WHO~2007~ grades may be strongly influenced by IDH-1^R132H\ mut^ status.

Previous studies suggested a strong correlation between IDH mutations and lower Ki-67 index, mutant p53 levels, and MGMT promoter methylation in gliomas \[[@R10], [@R16], [@R19], [@R24]--[@R26]\]. Here, we found that lower Ki-67 was associated with IDH^R132H\ mut^ in all WHO~2007~ glioma subtypes. However, mutant p53 expression in astrocytic tumors only differed after patients were grouped based on IDH-1^R132H^ mutation status. It is well-established that IDH mutations are associated with MGMT promoter methylation \[[@R10], [@R26]--[@R28]\]. In the present study, an association between IDH-1^R132H\ mut^ and MGMT protein levels was observed in glioma overall, but not within the glioma subtypes. These differences may be due to differences in the sensitivity of the detection methods \[[@R26], [@R29]\]. However, our results indicate that combining IDH-1^R132H^ status with Ki-67 index and mutant p53 and MGMT protein levels could improve prognosis predictions in glioma patients.

Recent data suggests that IDH-1 mutations, Ki-67 index, and MGMT protein levels are prognostic factors for diffuse gliomas \[[@R15], [@R20], [@R22], [@R24], [@R30]--[@R32]\]. Cai *et al.* found that IDH-wt plus Ki-67-low and IDH-wt plus Ki-67-high astrocytic tumor patients had different clinical outcomes. The cutoff for Ki-67 in their study was 10%, and median survival was about 2 years in Ki-67-low and 1 year Ki-67-high patients \[[@R32]\]. Zeng *et al.* observed that Ki-67≥30 was associated with worse prognosis in both IDH mut (median OS=566 days) and IDH wt (median OS=355 days) groups. The median OS in our study was closer to that found by Zeng *et al*. These results indicate that Ki-67 index is a reliable candidate for determining prognosis in glioma patients in addition to IDH-1 status. Although the prognostic value of MGMT protein levels is controversial \[[@R29]\], we found here that they were predictive of prognosis. Different IHC detection thresholds may help explain this discrepancy.

In summary, we characterized the expression of IDH-1^R132H\ mut^ in a large cohort of glioma patients. IDH-1^R132H\ mut^ was associated with specific WHO~2007~ histological grades and younger age. Age differences between different WHO~2007~ grades of astrocytoma were strongly influenced by IDH-1^R132H^ mutation status. Low Ki-67 index values occurred much more often in patients with lower WHO~2007~ grades and IDH-1^R132H^ mutation. Finally, our study indicated that Ki-67 index and MGMT protein levels, together with IDH mutation status, were predictive of prognosis in different glioma subtypes.

MATERIALS AND METHODS {#s4}
=====================

Patients and tumor samples {#s4_1}
--------------------------

Tumor samples were obtained from Sanbo Brain Hospital. Informed consent was obtained from all patients prior to the study. All experiments using human tissues were approved by the Institutional Review Board of Sanbo Brain Hospital. 670 adult patients with diffuse supratentorial gliomas were involved in the study. WHO classification of all specimens was performed by two independent neuropathologists \[[@R2]\]. In the case of a discrepancy, the two observers simultaneously reviewed the slides until a consensus was achieved. Clinical data, including patients' age at diagnosis, sex, and molecular pathology, were collected. The diagnosis of GBMO (glioblastoma with an oligodendroglioma component) was made as previously described \[[@R33]\]. OS (overall survival) was measured from the date of operation to the death or the last known follow-up.

Evaluation of IDH-1^R132H\ mut^, MGMT, mutant P53, and Ki-67 levels by immunohistochemistry {#s4_2}
-------------------------------------------------------------------------------------------

Experimental procedures were performed as described previously \[[@R34]--[@R36]\]. Primary antibodies against IDH1^R132H^ (Dianova 1:100), p53 (1:100 Invitrogen), MGMT (1:150 Invitrogen), and Ki-67 (1:200 Invitrogen) were used. The cutoff values were 10% for IDH-1^R132H\ mut^, 10% for mutant p53, 10% for MGMT, and 30% for Ki-67. Representative images of high and low IDH-1^R132H\ mut^ (Figure [3a](#F3){ref-type="fig"}, [3b](#F3){ref-type="fig"}), Ki-67 (Figure [3c](#F3){ref-type="fig"}, [3d](#F3){ref-type="fig"}), mutant p53 (Figure [3e](#F3){ref-type="fig"}, [3f](#F3){ref-type="fig"}), and MGMT protein (Figure [3g](#F3){ref-type="fig"}, [3h](#F3){ref-type="fig"}) levels in glioblastoma patients are shown.

![Examples of IDH-1^R132H\ mut^, Ki-67 index, and mutant p53 and MGMT protein levels in glioblastomas\
IDH-1R132H mut positive **a.** and negative **b.** Ki-67 50%-60% **c.** and 20% **d.** mutant p53 positive **e.** and negative **f.** MGMT positive **g.** and negative **f.**](oncotarget-07-31393-g003){#F3}

Statistics {#s4_3}
----------

SPSS 22.0 was used for all statistical analyses. The χ^2^ test was applied to assess the co-occurrence of IDH-1 mutation patient characteristics or the presence of other disease biomarkers. Survival curves were analyzed by the Kaplan-Meier method and the Breslow test. A *p*\<0.05 (two-sided) was considered statistically significant.
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